Business Wire

Terumo BCT Completes the First Clinical Study Reducing Malaria Transmission from Whole Blood Transfusions with Pathogen Reduction Technology

Del

In low-income countries, 69 percent of collected blood is transfused as whole blood (WB) rather than blood components.1 However, health care professionals have had no proven method to inactivate harmful pathogens and donor white blood cells in WB. This puts patients at risk for contracting diseases and experiencing complications during transfusions. To help advance blood safety, Terumo BCT has recently completed the first and only clinical trial to demonstrate that a pathogen reduction technology—specifically the company’s Mirasol® Pathogen Reduction Technology (PRT) System—can effectively reduce the incidence of transfusion-transmitted infection (TTI) of malaria in WB.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151027006791/en/

Mirasol PRT System (Photo: Business Wire)

Mirasol PRT System (Photo: Business Wire)

Following the success of the Ghana clinical trial, called the African Investigation of Mirasol System (AIMS), Terumo BCT applied for the CE Mark for the Mirasol PRT system for treatment of WB. Prior to this new protocol, blood centers and hospitals in 18 countries across four continents have used the system to treat platelets and plasma.

A safe blood supply is needed for many health care procedures. While low- and middle-income nations account for 82 percent of the world’s population, they collect only approximately half of the blood donations worldwide.2 Furthermore, blood centers in these nations often do not have the latest technologies to test blood extensively for harmful pathogens.

Terumo BCT performed the AIMS trial at Komfo Anokye Teaching Hospital in Kumasi, Ghana. The study tested the ability of the Mirasol PRT system to demonstrate a reduction in TTI of malaria in WB transfusions, which has been demonstrated to occur in up to 28 percent of blood recipients in the region today.3 While no blood safety measure can completely eliminate the risk of TTIs, the subject group in the trial that received Mirasol-treated WB showed a statistically and clinically significant reduction in TTI of malaria compared to the subject group that received untreated WB.4

Additionally, the incidence in the trial of adverse events from the transfused blood products was similar between the treated and untreated groups.

The Mirasol PRT system for treatment of WB demonstrates a new opportunity to advance global blood safety and fight the spread of malaria. Blood centers without the technologies to test blood for harmful pathogens could use this technology to overcome that limitation and reduce the incidence of TTI of malaria in ways never before available.

The Mirasol PRT system for treatment of WB was developed with the support of the U.S. Department of Defense (DoD) through grants and contracts with the U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland. Studies are ongoing to support an application by Terumo BCT to gain U.S. Food and Drug Administration (FDA) approval for the clinical use of red blood cells derived from treated WB. If the application is approved, the Mirasol PRT system will be used in applications such as field hospital settings to support transfusions for military personnel under austere conditions.

KEY FACTS:

  • Terumo BCT applied for the CE Mark for the Mirasol PRT system for treatment of WB, and an ongoing clinical study is progressing in the U.S. to evaluate the Mirasol PRT system for red blood cells derived from treated WB
  • Terumo BCT recently completed the first and only clinical trial to demonstrate that the Mirasol PRT system can effectively reduce the incidence of TTI of malaria
  • No method of testing or pathogen reduction can completely eliminate the risk of a TTI, but the AIMS study showed a clinically and statistically significant reduction of TTI of malaria incidence in the treated group versus the untreated group
  • The Mirasol PRT system uses a combination of riboflavin (vitamin B2) and ultraviolet light to inactivate viruses, bacteria, parasites and white blood cells that may be present in collected blood products
  • Health care professionals are using the Mirasol PRT system to treat platelets and plasma in more than 70 centers across 18 countries in Europe, the Middle East, South America, Central America and Asia
  • The Mirasol PRT system for treatment of WB development program is partially funded by the U.S. Department of Defense

AIMS STUDY METHODOLOGY:

  • The AIMS trial was a prospective, randomized, double-blind, controlled, single-center study in which subjects received ≤2 transfusions of either Mirasol-treated fresh whole blood (MIR-WB) or fresh WB prepared by standard-of-care methods
  • In the AIMS trial, 223 subjects received trial-related blood transfusions; 111 subjects received MIR-WB and 112 subjects received WB prepared by standard-of-care methods
  • Subjects were followed for 28 days post-transfusion

KEY QUOTES:

David Perez, President and CEO, Terumo BCT

“Terumo BCT is committed to improving blood safety around the world as a part of our industry promise of ‘Unlocking the potential of blood.’ The need for global blood safety inspired us to complete the AIMS trial, which makes new safety measures available to blood centers. Safer transfusions could translate to less disease, especially for high-risk patient populations like pregnant women, children and trauma victims. Pathogen Reduction Technology through our Mirasol system is one of several initiatives at Terumo BCT to improve blood safety. It is an honor to work in collaboration with our customers to improve patient and clinical outcomes and advance this area of health care.”

Ray Goodrich, PhD, Chief Scientific Officer, Terumo BCT

“The success of the AIMS trial is due to the collaboration of Terumo BCT, Cambridge University, Komfo Anokye Teaching Hospital and the Republic of Ghana. The Mirasol PRT system can enable blood centers to provide safer transfusions despite challenges with access to the blood supply and testing of blood products. This trial is the first to demonstrate significant pathogen reduction in whole blood, marking an important milestone in blood safety.”

Dr. Shirley Owusu-Ofori, Head of the Transfusion Medicine Unit, Komfo Anokye Teaching Hospital

“This clinical trial will provide evidence that may greatly advance the provision of safe blood in Ghana, as well as other developing countries. Terumo BCT's Mirasol PRT system was shown to be effective in this study and has the potential to improve the safety of whole blood. I am hopeful that this system can minimize the residual risk for high-prevalence infections and pathogens, such as malaria, where no screening currently exists that is practical for blood banking in Sub-Saharan Africa.”

About Terumo BCT:

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

1 Hume H, et al., Chapter 53: “Blood Transfusion in Economically Restricted and Developing Countries,” Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects, 2013, second edition, Elsevier Inc., Amsterdam, Netherlands.

2 World Health Organization, “Blood Safety and Availability,” http://www.who.int/mediacentre/factsheets/fs279/en/, accessed on 11 September 2015.

3 Freimanis G, et al., “Investigating the Prevalence of Transfusion Transmission of Plasmodium within a Hyperendemic Blood Donation System,” Transfusion 2013; 53 (7): 1429–1441.

4 Allain JP, et al., manuscript in preparation.

Contact information

Terumo BCT
D.J. Martin, +1-303-239-2060
Global Corporate Communications
press@terumobct.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease18.7.2018 21:45Pressemelding

VIEW E-MEDIA KIT – Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. The article reports results that showed significantly fewer sickle cell crises in those receiving Endari compared to placebo by 25 percent; p=0.005 (median 3 vs. median 4) and significantly fewer hospitalizations by 33 percent; p=0.005 (median 2 vs. median 3). Additional findings showed lower cumulative days in hospital of 41 percent; p=0.02 (median 6.5 days vs. median 11 days) and a lower incidence of acute chest syndrome (ACS) by more than 60 percent; p=0.003 (13 of 152 patients [8.6%] had at least 1 ACS compared with 18 of 78 in the placebo group [23.1%]). The most common adverse reactions, occurring in great

Tigo Releases State-of-the-art Wireless Technology – Mesh – as the New Solar Communication Architecture for the TS4 Platform18.7.2018 19:41Pressemelding

Tigo®, pioneer of the smart modular Flex MLPE platform, today announced the release of its new Mesh communication architecture. This state-of-the-art wireless technology directly translates to customer benefits – including simplifying the solar design process and accelerating the commissioning steps. The complete Tigo solution uses a simple yet powerful data collection technology that covers the widest ranges of residential & commercial installations at the lowest cost. With Mesh and the recently announced Tigo Access Point (TAP), customers eliminate the need to address any roof obstruction or orientation constraint. To learn more about Mesh and TAP, register for Tigo’s free, online webinar “The Future of Solar is Wireless” on Wednesday July 25th, 2018 at 10am PDT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180718005827/en/ Mesh is Tigo's proprietary software that allows each TS4 unit to act as a repeater, extending the

ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 201818.7.2018 17:21Pressemelding

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands. The data being presented this year has a strong focus on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding of key issues that continue to affect the HIV community. John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, “As we see advancements in the treatment options available to people living with HIV, our research efforts over the past few years have been focused on moving beyond viral load and addressing some of the unresolved issues that people living with HIV face, such as the potential long-term risks and toxicities that can be associated with li

Xilam: H1 2018 Revenue: +50%18.7.2018 16:00Pressemelding

Regulatory News: The Xilam Group (Paris:XIL) posted consolidated H1 2018 revenue of EUR 13,866 thousand, an increase of 50%. This increase represents an excellent performance, as it follows on the heels of growth of 54% in H1 2017. Revenue for the first part of this financial year breaks down as follows. In thousands of euros 30.06.2018 (1) 30.06.2017 Change New productions 8,465 4,571 +85% Catalogue 5,385 4,652 +16% Other 16 16 +0% Revenue and subsidies 13,866 9,239 +50% (1) Unaudited data. Remarkable success for new releases +85% Excellent H1 growth was driven by the two main businesses, New Productions and Catalogue. In New Productions, H1 deliveries generated record revenue of EUR 8,465 thousand, an 85% increase compared with H1 2017, and confirmed Xilam’s position as a major European animation company. Catalogue revenue was up 16% compared with H1 2017, thanks again to traditional TV channels and digital platforms, in both France and abroad. A fast-paced delivery schedule Thanks t

Department for International Trade: Life Sciences at the Heart of UK Economy18.7.2018 12:38Pressemelding

The Government will today (Wednesday 18 July) host the second in a series of roundtables with stakeholders from key life science businesses, demonstrating the importance of the sector to the UK economy. The Chancellor, International Trade Secretary, Business Secretary and Health and Social Care Secretary will be amongst those that meet with senior representatives from leading UK and international life sciences companies as the UK positions itself as the global home of health innovation, welcoming overseas investment and seeking to boost exports in the process. Discussions at the roundtable will focus on how the future of the Life Sciences sector will be supported by the delivery of our modern Industrial Strategy, ensuring that the UK is ‘open for business’ with a positive business environment, our ambitions for a comprehensive agreement with the EU on our future relationship and the development and implementation of our independent trade policy. To date, the government has engaged sign

Universal Laser Systems Expands Its Materials Database with 3M, Victrex and Dexmet Materials18.7.2018 12:05Pressemelding

Universal Laser Systems (ULS) announces the addition of 3M™, Victrex® and Dexmet materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The 3M, Victrex and Dexmet materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: 3M™ Extreme Sealing Tape 4412N 3M™ Thermally Conductive Silicone Interface Pad 5516 Victrex® APTIV® PEEK Film Dexmet PolyGrid® 8PTFE10-125ST Expanded PTFE Dexmet MicroGrid® AL 25 Expanded Aluminum Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advantages of deploying laser technology within their manufacturing, research and d